# mc-Val-Cit-PABC

Source: https://onco.cc/terms/mc-vc-pabc/  
OnCo record `mc-vc-pabc` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The mc-Val-Cit-PABC linker is the workhorse of the vedotin ADCs: a valine-citrulline dipeptide cut by cathepsin B, releasing MMAE with a bystander effect.

## Summary

Maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamate links through cysteine thiols, is stable in human plasma, and is cleaved by cathepsins in the lysosome. In mice it is cleaved prematurely by a serum carboxylesterase, which complicated early preclinical testing. Neutropenia is partly attributed to premature release near neutrophil elastase.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: valine-citrulline linker; vc-MMAE; mc-VC-PABC

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Brentuximab_vedotin
- Monoclonal antibody auristatin (vc-MMAE) conjugates (Doronina et al., Nature Biotechnology 2003): https://doi.org/10.1038/nbt832

## Connected records

- terms: [Bystander effect (ADC)](https://onco.cc/terms/bystander-effect/), [Linker (ADC)](https://onco.cc/terms/linker/), [MMAE](https://onco.cc/terms/mmae/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/), [Tisotumab vedotin](https://onco.cc/drugs/tisotumab-vedotin/)
- key papers: [Development of potent monoclonal antibody auristatin conjugates for cancer therapy](https://onco.cc/key-papers/paper-doronina-nat-biotechnol/)

---
JSON: https://onco.cc/api/v1/entities/mc-vc-pabc.json